Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38.
about
Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer.Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.Body mass index and breast cancer survival: a Mendelian randomization analysis.Longitudinal patterns and associated factors of postdiagnosis weight changes in Korean breast cancer survivors with normal body mass index.Impact of body composition on outcome in patients with early breast cancer.
P2860
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Body Mass Index at Diagnosis a ...... BP B-30, B-31, B-34, and B-38.
@ast
Body Mass Index at Diagnosis a ...... BP B-30, B-31, B-34, and B-38.
@en
type
label
Body Mass Index at Diagnosis a ...... BP B-30, B-31, B-34, and B-38.
@ast
Body Mass Index at Diagnosis a ...... BP B-30, B-31, B-34, and B-38.
@en
prefLabel
Body Mass Index at Diagnosis a ...... BP B-30, B-31, B-34, and B-38.
@ast
Body Mass Index at Diagnosis a ...... BP B-30, B-31, B-34, and B-38.
@en
P2093
P2860
P50
P1476
Body Mass Index at Diagnosis a ...... BP B-30, B-31, B-34, and B-38.
@en
P2093
Alexander H G Paterson
Barry C Lembersky
Charles E Geyer
Edward H Romond
Joseph P Costantino
Norman Wolmark
Priya Rastogi
P2860
P356
10.1158/1055-9965.EPI-15-0334-T
P577
2015-11-06T00:00:00Z